Inpharmatica secures ADME agreement with British Biotech
Inpharmatica, the selective drug discovery company, has entered into a two-year agreement with British Biotech, the LSE and NASDAQ listed biopharmaceutical company, for the provision of ADME (absorption, distribution, metabolism and excretion) services in connection with its drug discovery activities.
Inpharmatica, the selective drug discovery company, has entered into a two-year agreement with British Biotech, the LSE and NASDAQ listed biopharmaceutical company, for the provision of ADME (absorption, distribution, metabolism and excretion) services in connection with its drug discovery activities.
Under the terms of the agreement, Inpharmatica's ADME team will provide assays, analysis and interpretation of ADME data for a number of different project teams at British Biotech. An experienced ADME consultant from Inpharmatica will form part of the British Biotech project teams and manage the interaction between the project teams and Inpharmatica's range of ADME services. ADME studies are an important component of the optimization phase of drug development. They help screen molecules for qualities that make them desirable as drug candidates and ultimately, drugs. Inpharmatica's recently acquired ADME capability extends its PharmaCarta chemogenomics platform, providing a more comprehensive range of services to customers and enhancing the Company's internal discovery capabilities.
Commenting on the announcement, Dr. Mike Tarbit, senior vice president - Preclinical r&d at Inpharmatica, said: 'We are delighted to be entering into this relationship with British Biotech. Inpharmatica's extensive lead optimisation experience underpins all of our in-vitro and in-silico technologies and enables us to offer state-of-the-art support to discovery companies such as British Biotech, who can then manage their ADME needs in a flexible and cost effective way.'
Commenting on the announcement, Dr David Knowles, r&d director of British Biotech, said: 'We have selected Inpharmatica to support our lead optimisation activities because they have a proven ability to assist the effective progression of a number of our discovery and lead optimisation programmes. Their expertise will be invaluable, not only at performing various in-vitro ADME assays but also in helping plan and interpret the results of pharmacokinetics experiments.'